These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 21813293)

  • 1. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
    Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
    J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy.
    Wang JS; Lee IT; Lee WJ; Lin SD; Su SL; Tu ST; Tseng YH; Lin SY; Sheu WH
    J Diabetes; 2017 Mar; 9(3):248-255. PubMed ID: 27043224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic excursions are positively associated with changes in duration of asymptomatic hypoglycemia after treatment intensification in patients with type 2 diabetes.
    Wang JS; Lee IT; Lee WJ; Lin SD; Su SL; Tu ST; Tseng YH; Lin SY; Sheu WH
    Diabetes Res Clin Pract; 2016 Mar; 113():108-15. PubMed ID: 26810269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin.
    Kusunoki Y; Katsuno T; Myojin M; Miyakoshi K; Ikawa T; Matsuo T; Ochi F; Tokuda M; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
    Endocr J; 2013; 60(4):431-9. PubMed ID: 23220949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.
    Wang MM; Lin S; Chen YM; Shu J; Lu HY; Zhang YJ; Xie RY; Zeng LY; Mu PW
    Diabetes Res Clin Pract; 2015 Jun; 108(3):e67-70. PubMed ID: 25841300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
    Wang W; Ning G; Ma J; Liu X; Zheng S; Wu F; Xu L; O'Neill EA; Fujita KP; Engel SS; Kaufman KD; Shankar RR
    Curr Med Res Opin; 2017 Apr; 33(4):693-699. PubMed ID: 28035868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ; Pans M; Rubin CJ
    Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin.
    Phillips P; Karrasch J; Scott R; Wilson D; Moses R
    Diabetes Care; 2003 Feb; 26(2):269-73. PubMed ID: 12547847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.
    Yang W; Liu J; Shan Z; Tian H; Zhou Z; Ji Q; Weng J; Jia W; Lu J; Liu J; Xu Y; Yang Z; Chen W
    Lancet Diabetes Endocrinol; 2014 Jan; 2(1):46-55. PubMed ID: 24622668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study.
    Lee MY; Choi DS; Lee MK; Lee HW; Park TS; Kim DM; Chung CH; Kim DK; Kim IJ; Jang HC; Park YS; Kwon HS; Lee SH; Shin HK
    J Korean Med Sci; 2014 Jan; 29(1):90-7. PubMed ID: 24431911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
    Bayraktar M; Van Thiel DH; Adalar N
    Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
    Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple oral antidiabetic therapy.
    Kaye TB
    J Diabetes Complications; 1998; 12(6):311-3. PubMed ID: 9877464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
    Kellerer M; Jakob S; Linn T; Haslbeck M
    MMW Fortschr Med; 2003 Dec; 145(51-52):I-X; quiz XI-XII. PubMed ID: 14974337
    [No Abstract]   [Full Text] [Related]  

  • 20. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes.
    Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Int J Obes Relat Metab Disord; 1997 Sep; 21(9):756-63. PubMed ID: 9376887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.